Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Atea Pharmaceuticals, Inc.
  6. Summary
    AVIR   US04683R1068

ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
Real-time Estimate Cboe BZX  -  03:26:12 2023-06-05 pm EDT
4.265 USD   -5.22%
05/30Atea Pharmaceuticals Rejects Acquisition Proposal From Tang Capital Partners Affiliate Concentra Biosciences
MT
05/30Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences
AQ
05/30Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc..
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/30/2023 05/31/2023 06/01/2023 06/02/2023 06/05/2023 Date
4.12(c) 3.99(c) 4.08(c) 4.5(c) 4.24 Last
1 103 737 2 246 708 651 794 1 290 963 433 177 Volume
-11.97% -3.16% +2.26% +10.29% -5.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 - - -
Net income 2023 -178 M - -
Net cash position 2023 522 M - -
P/E ratio 2023 -2,11x
Yield 2023 -
Sales 2024 21,6 M - -
Net income 2024 -239 M - -
Net cash position 2024 526 M - -
P/E ratio 2024 -1,59x
Yield 2024 -
Capitalization 375 M 375 M -
EV / Sales 2023 -
EV / Sales 2024 -6,97x
Nbr of Employees 73
Free-Float 90,8%
More Financials
Company
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in developing its product candidate, bemnifosbuvir, for the treatment of coronavirus disease 2019 (COVID-19), and its variants. The Company is also... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/16 | 09:00amAis meeting general
More about the company
Ratings of Atea Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about ATEA PHARMACEUTICALS, INC.
05/30Atea Pharmaceuticals Rejects Acquisition Proposal From Tang Capital Partners Affiliate ..
MT
05/30Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from ..
AQ
05/30Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceut..
CI
05/23Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partner..
AQ
05/22Atea Pharmaceuticals Receives Cash Takeover Proposal From Tang Capital Affiliate Concen..
MT
05/22Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in ..
CI
05/08ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/08Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/08Transcript : Atea Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 08, 2023
CI
05/08Atea Pharmaceuticals : First Quarter 2023 Financial Results Conference Call Presentation
PU
05/08Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business..
AQ
05/01Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on Ma..
AQ
04/25Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir..
AQ
04/25Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to Bemnifo..
CI
04/12Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalization..
AQ
More news
News in other languages on ATEA PHARMACEUTICALS, INC.
05/30Concentra Biosciences, LLC a annulé l'acquisition d..
05/22Atea Pharmaceuticals reçoit une proposition de rachat en numéraire de la part de Concen..
05/08Atea Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
04/25Atea Pharmaceuticals, Inc. annonce que la FDA des États-Unis a accordé la désignation F..
03/14Atea Pharmaceuticals, Inc. présente de nouvelles données sur le profil favorable du bem..
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on ATEA PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Products ETF - USD0.68%1.99%United_States
Virtus LifeSci Biotech Clinical Trials ETF - USD0.68%2.42%United_States
IShares Genomics Immunology and Healthcare ...0.63%2.16%World
First Trust Dow Jones Select MicroCap Index...0.43%3.14%United_States
ETFMG Treatments Testing and Advancements E...0.38%4.06%-NC
More ETFs positioned on ATEA PHARMACEUTICALS, INC.
Chart ATEA PHARMACEUTICALS, INC.
Duration : Period :
Atea Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATEA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 4,50 $
Average target price 6,25 $
Spread / Average Target 38,9%
EPS Revisions
Managers and Directors
Jean-Pierre Sommadossi Chairman, President & Chief Executive Officer
Andrea J. Corcoran Executive Vice President-Legal & Administration
Maria Arantxa Horga Executive Vice President-Clinical Sciences
Keith Pietropaolo Senior Vice President-Clinical Operations
Claudio Avila Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ATEA PHARMACEUTICALS, INC.-6.44%375
VERTEX PHARMACEUTICALS INCORPORATED15.58%85 966
REGENERON PHARMACEUTICALS, INC.2.56%79 256
WUXI APPTEC CO., LTD.-16.25%28 067
BIONTECH SE-28.02%26 058
GENMAB A/S-7.45%25 588
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer